🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

111 results for “Novo” Clear

  1. coramitug C 10035, liquid dosage form in 20 mL vials with 11 extractable volume

    Novo Nordisk A/S

    Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy

    phase 3 small molecule active

    1 trial

  2. ziltivekimab, Placebo (ziltivekimab C)

    Novo Nordisk A/S

    Heart failure with mildly reduced or preserved ejection fraction and systemic inflammation

    phase 3 small molecule active

    1 trial

  3. ziltivekimab, Ziltivekimab

    Novo Nordisk A/S

    The medical condition we are investigating is type 1 AMI (STEMI and NSTEMI). Ziltivekimab is a human monoclonal antibody directed against the interleukin-6 (IL-6) ligand, and currently available clinical data support that ziltivekimab once-monthly reduces inflammation as measured by highsensitivity C-reactive protein (hs-CRP). With the recent proof-of-concept that hs-CRP reduction through inhibition of an upstream pathway leads to reduction in cardiovascular events, it is reasonable to expect that similar inhibition of IL-6 with ziltivekimab also reduces CV risk.The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST-elevation and non-ST-elevation myocardial infarction

    phase 3 small molecule active

    1 trial

  4. Decitabine/Tetrahydrouridine A 5/250 mg, Siklos 1 000 mg film-coated tablet., Placebo (NDec)

    Novo Nordisk A/S

    Sickle cell disease

    phase 2 small molecule active

    1 trial

  5. GADOTERIC ACID , PARACETAMOL , coramitug, CETIRIZINE , SODIUM CHLORIDE

    Novo Nordisk A/S

    Participants with transthyretin amyloid cardiomyopathy (ATTR CM)

    phase 2 small molecule active

    1 trial

  6. Matched Placebo

    Novo mesto

    Mechanical allodynia

    phase 2 small molecule active

    1 trial

  7. Novo Nordisk GlucaGen®

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  8. Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.

    Novo Nordisk A/S

    Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.

    phase 2 other active

    1 trial

  9. Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy.

    Novo Nordisk A/S

    Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left Ventricular Hypertrophy.

    phase 2 other active

    1 trial

  10. Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide

    Novo Nordisk A/S

    Type 2 diabetes and painful diabetic peripheral neuropathy

    phase 2 small molecule active

    1 trial

  11. Placebo A, NNC0487-0111, NNC0487-0111, NNC0487-0111, Placebo C tablets, NNC0487-0111, METFORMIN , NNC0487-0111, NNC0487-0111, NNC0487-0111, DAPAGLIFLOZIN , NNC0487-0111

    Novo Nordisk A/S

    Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  12. Placebo A, NNC0519-0130, Ozempic 0.5 mg solution for injection in pre-filled pen

    Novo Nordisk A/S

    Chronic Kidney Disease, with or without Type 2 diabetes, Obesity

    phase 2 small molecule active

    1 trial

  13. Placebo A, Semaglutide B Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen

    Novo Nordisk A/S

    type 2 diabetes

    phase 2 small molecule active

    1 trial

  14. Placebo C, Semaglutide B 3.0 mg/ml PDS290, Semaglutide B placebo PDS290 pen-injector, Cagrilintide A 10 mg/mL cartridge, NNC0174-0833 A Placebo

    Novo Nordisk A/S

    Non-alcoholic steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  15. Product

    Novo mesto

    Women with an indication for IVF/ICSI

    phase 2 small molecule active

    1 trial

  16. Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen, Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen

    Novo Nordisk A/S

    SGA - small for gestational age children

    phase 2 small molecule active

    1 trial

  17. cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide, semaglutide, cagrilintide, cagrilintide, cagrilintide semaglutide, cagrilintide semaglutide, semaglutide, semaglutide, semaglutide, FINERENONE , DAPAGLIFLOZIN , semaglutide, cagrilintide, ENALAPRIL , cagrilintide, cagrilintide, cagrilintide semaglutide

    Novo Nordisk A/S

    Chronic Kidney Disease, Type 2 diabetes

    phase 2 small molecule active

    1 trial

  18. cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, Placebo (zalfermin) + Placebo (semaglutide), semaglutide, Placebo (cagrilintide) + placebo (semaglutide), cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, zalfermin, cagrilintide, cagrilintide

    Novo Nordisk A/S

    alcohol-related liver disease

    phase 2 small molecule active

    1 trial

  19. etavopivat B 10041, etavopivat B 10042

    Novo Nordisk A/S

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  20. A Phase 1b Study of AMG 757 in Subjects with Neuroendocrine Prostate Cancer

    Amgen Technology (Ireland) UC

    Adult subjects with de novo or treatment-emergent neuroendocrine prostate cancer

    phase 1 other active

    1 trial

  21. A first human dose study to assess the safety, tolerability, pharmacokinetics and target engagement of single doses of NNC6022-0001 in healthy adults

    Novo Nordisk A/S

    Cardiometabolic diseases

    phase 1 other active

    1 trial

  22. A research study Looking into blood levels of the medicine NNC0519-0130 in the body of participants with normal or reduced kidney function

    Novo Nordisk A/S

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  23. A research study comparing different ways of increasing the dose of NNC0519-0130 in participants with overweight or obesity

    Novo Nordisk A/S

    Type 2 diabetes mellitus

    phase 1 other active

    1 trial

  24. A research study investigating the effect of NNC0497-0040 in healthy participants, participants with overweight or obesity, and participants with type 1 diabetes with overweight or obesity.

    Novo Nordisk A/S

    Type I diabetes

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources